Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Parallel-group Study, to Compare Pharmacokinetics, Safety and Immunogenicity of CMAB807 Injection Versus Prolia® in Healthy Chinese Male Subjects.

NCT03925051 is registered in ClinicalTrials.gov with Shanghai Biomabs Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03925051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03925051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Parallel-group Study, to Compare Pharmacokinetics, Safety and Immunogenicity of CMAB807 Injection Versus Prolia® in Healthy Chinese Male Subjects.
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2019
Completion date
June 18, 2020
Enrollment
132 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis